Tobacco Use — Identify the Usefulness of In-person and Virtual Quit Smoking Programs
Citation(s)
Bandura A Social cognitive theory: an agentic perspective. Annu Rev Psychol. 2001;52:1-26. doi: 10.1146/annurev.psych.52.1.1.
Blanco C, Olfson M, Goodwin RD, Ogburn E, Liebowitz MR, Nunes EV, Hasin DS Generalizability of clinical trial results for major depression to community samples: results from the National Epidemiologic Survey on Alcohol and Related Conditions. J Clin Psychiatry. 2008 Aug;69(8):1276-80. doi: 10.4088/jcp.v69n0810.
Broadhead WE, Gehlbach SH, de Gruy FV, Kaplan BH The Duke-UNC Functional Social Support Questionnaire. Measurement of social support in family medicine patients. Med Care. 1988 Jul;26(7):709-23. doi: 10.1097/00005650-198807000-00006.
Burns EK, Deaton EA, Levinson AH Rates and reasons: disparities in low intentions to use a state smoking cessation quitline. Am J Health Promot. 2011 May-Jun;25(5 Suppl):S59-65. doi: 10.4278/ajhp.100611-QUAN-183.
Centers for Disease Control and Prevention (CDC) Tobacco product use among middle and high school students--United States, 2011 and 2012. MMWR Morb Mortal Wkly Rep. 2013 Nov 15;62(45):893-7. Erratum In: MMWR Morb Mortal Wkly Rep. 2013 Nov 22;62(46):940.
Cokkinides VE, Halpern MT, Barbeau EM, Ward E, Thun MJ Racial and ethnic disparities in smoking-cessation interventions: analysis of the 2005 National Health Interview Survey. Am J Prev Med. 2008 May;34(5):404-12. doi: 10.1016/j.amepre.2008.02.003.
Cokkinides VE, Ward E, Jemal A, Thun MJ Under-use of smoking-cessation treatments: results from the National Health Interview Survey, 2000. Am J Prev Med. 2005 Jan;28(1):119-22. doi: 10.1016/j.amepre.2004.09.007.
Corey CG, Ambrose BK, Apelberg BJ, King BA Flavored Tobacco Product Use Among Middle and High School Students--United States, 2014. MMWR Morb Mortal Wkly Rep. 2015 Oct 2;64(38):1066-70. doi: 10.15585/mmwr.mm6438a2.
Cummings KM, Orleans CT Policies to Achieve a Smoke-Free Society: A Research Agenda for 2010-2015. 2009.
Elfeddali I, Bolman C, Candel MJ, Wiers RW, De Vries H The role of self-efficacy, recovery self-efficacy, and preparatory planning in predicting short-term smoking relapse. Br J Health Psychol. 2012 Feb;17(1):185-201. doi: 10.1111/j.2044-8287.2011.02032.x. Epub 2011 Jun 27.
Fagerstrom KO, Schneider NG Measuring nicotine dependence: a review of the Fagerstrom Tolerance Questionnaire. J Behav Med. 1989 Apr;12(2):159-82. doi: 10.1007/BF00846549.
Ford P, Clifford A, Gussy K, Gartner C A systematic review of peer-support programs for smoking cessation in disadvantaged groups. Int J Environ Res Public Health. 2013 Oct 28;10(11):5507-22. doi: 10.3390/ijerph10115507.
Gücin NÖ, Berk ÖS Technology Acceptance in Health Care: An Integrative Review of Predictive Factors and Intervention Programs. 2015. Procedia - Social and Behavioral Sciences, 195, pp. 1698-1704.
Henry SA , Sheikhattari P, Wagner FA. Analyzing disparities on tobacco use through CBPR. Drug & Alcohol Dependence. 2015; 146, p. e140.
Jain A Treating nicotine addiction. BMJ. 2003 Dec 13;327(7428):1394-5. doi: 10.1136/bmj.327.7428.1394. No abstract available.
McKay CE, Dickerson F Peer Supports for Tobacco Cessation for Adults with Serious Mental Illness: A Review of the Literature. J Dual Diagn. 2012;8(2):104-112. doi: 10.1080/15504263.2012.670847. Epub 2012 May 11.
Moberg J, Kramer M A brief history of the cluster randomised trial design. J R Soc Med. 2015 May;108(5):192-8. doi: 10.1177/0141076815582303. No abstract available.
O'Toole TP, Aaron KF, Chin MH, Horowitz C, Tyson F Community-based participatory research: opportunities, challenges, and the need for a common language. J Gen Intern Med. 2003 Jul;18(7):592-4. doi: 10.1046/j.1525-1497.2003.30416.x. No abstract available.
Orleans CT Increasing the demand for and use of effective smoking-cessation treatments reaping the full health benefits of tobacco-control science and policy gains--in our lifetime. Am J Prev Med. 2007 Dec;33(6 Suppl):S340-8. doi: 10.1016/j.amepre.2007.09.003.
Ramo DE, Liu H, Prochaska JJ A mixed-methods study of young adults' receptivity to using Facebook for smoking cessation: if you build it, will they come? Am J Health Promot. 2015 Mar-Apr;29(4):e126-35. doi: 10.4278/ajhp.130326-QUAL-128. Epub 2014 Feb 27.
Ranney L, Melvin C, Lux L, McClain E, Lohr KN Systematic review: smoking cessation intervention strategies for adults and adults in special populations. Ann Intern Med. 2006 Dec 5;145(11):845-56. doi: 10.7326/0003-4819-145-11-200612050-00142. Epub 2006 Sep 5.
Raw M, McNeill A, West R Smoking cessation: evidence based recommendations for the healthcare system. BMJ. 1999 Jan 16;318(7177):182-5. doi: 10.1136/bmj.318.7177.182. No abstract available.
Wagner F, Sheikhattari P 1968 - Improving the retention rates of two evidence-based smoking cessation trials designed through a participatory approach. European Psychiatry. 2013; 28(Supplement 1), p. 1.
West R, Sohal T "Catastrophic" pathways to smoking cessation: findings from national survey. BMJ. 2006 Feb 25;332(7539):458-60. doi: 10.1136/bmj.38723.573866.AE. Epub 2006 Jan 27.
Assessing the Effectiveness of Virtual Versus In-person Peer-motivation Smoking Cessation Interventions
Interventional studies are often prospective and are specifically tailored to evaluate direct impacts of treatment or preventive measures on disease.
Observational studies are often retrospective and are used to assess potential causation in exposure-outcome relationships and therefore influence preventive methods.
Expanded access is a means by which manufacturers make investigational new drugs available, under certain circumstances, to treat a patient(s) with a serious disease or condition who cannot participate in a controlled clinical trial.
Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.
Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.